Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer

Inclusion Criteria: * Age 18 or older * Stage III and IV head and neck cancer * Patients with squamous cell carcinoma of unknown primary and suspected origin in the head and neck area * No prior chemotherapy or radiotherapy * Prior surgical therapy of incisional or excisional biopsy and organ-sparing procedures only * Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2 * Normal organ and marrow function Exclusion Criteria: * Unequivocal demonstration of metastatic disease * Known severe hypersensitivity to drugs used in the study * Treatment with a non-approved or investigational drug within 30 days before Day 1 * Incomplete healing from previous surgery * Pregnancy or breast feeding * Uncontrolled intercurrent illness including * Patients with clinically significant pulmonary dysfunction, cardiomyopathy, or any history of clinically significant CHF * Acute hepatitis or known HIV * Severe baseline neurologic deficits * Prior therapy which specifically and directly targets the EGFR pathway * Prior severe infusion reaction to a monoclonal antibody